每年研究成果
每年研究成果
- 7結果
搜尋結果
-
2024
Correction to: The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells (Cell Death & Disease, (2013), 4, 9, (e810), 10.1038/cddis.2013.330)
Chen, M. C., Chen, C. H., Wang, J. C., Tsai, A. C., Liou, J. P., Pan, S. L. & Teng, C. M., 7月 2024, 於: Cell Death and Disease. 15, 7, 490.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取 -
2023
Erratum: N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of Transcription 3 (STAT3) Signaling (J. Med. Chem. (2015) 58:16 (6549−6558) DOI: 10.1021/acs.jmedchem.5b00659)
Lai, M. J., Lee, H. Y., Chuang, H. Y., Chang, L. H., Tsai, A. C., Chen, M. C., Huang, H. L., Wu, Y. W., Teng, C. M., Pan, S. L., Liu, Y. M., Mehndiratta, S. & Liou, J. P., 5月 11 2023, 於: Journal of Medicinal Chemistry. 66, 9, p. 6436 1 p.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取1 引文 斯高帕斯（Scopus） -
2020
Correction: Role of integrin-linked kinase in regulating the protein stability of the MUC1-C oncoprotein in pancreatic cancer cells (Oncogenesis, (2017), 6, 7, (e359), 10.1038/oncsis.2017.61)
Huang, H. L., Wu, H. Y., Chu, P. C., Lai, I. L., Huang, P. H., Kulp, S. K., Pan, S. L., Teng, C. M. & Chen, C. S., 2月 1 2020, 於: Oncogenesis. 9, 2, 27.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取 -
Corrigendum to: TW-01, a piperazinedione-derived compound, inhibits Ras-mediated cell proliferation and angioplasty-induced vascular restenosis “Toxicol Appl Pharmacol. 2016;305:194–202” (Toxicology and Applied Pharmacology (2016) 305 (194–202)(S0041008X16301478)(10.1016/j.taap.2016.06.013))
Lin, C. F., Huang, H. L., Peng, C. Y., Lee, Y. C., Wang, H. P., Teng, C. M. & Pan, S. L., 1月 15 2020, 於: Toxicology and Applied Pharmacology. 387, 114858.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取 -
Corrigendum to “1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma” [Eur. J. Med. Chem. 140 (2017) 84–91](S0223523417306931)(10.1016/j.ejmech.2017.09.011)
Liu, Y. M., HuangFu, W. C., Huang, H. L., Wu, W. C., Chen, Y. L., Yen, Y., Huang, H. L., Nien, C. Y., Lai, M. J., Pan, S. L. & Liou, J. P., 9月 15 2020, 於: European Journal of Medicinal Chemistry. 202, 112633.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取1 引文 斯高帕斯（Scopus） -
Corrigendum to“Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo”[Eur. J. Med. Chem. 190 (2020 Mar 15) 112086] (European Journal of Medicinal Chemistry (2020) 190, (S0223523420300532), (10.1016/j.ejmech.2020.112086))
Ojha, R., Nepali, K., Chen, C. H., Chuang, K. H., Wu, T. Y., Lin, T. E., Hsu, K. C., Chao, M. W., Lai, M. J., Lin, M. H., Huang, H. L., Chang, C. D., Pan, S. L., Chen, M. C. & Liou, J. P., 9月 1 2020, 於: European Journal of Medicinal Chemistry. 201, 112404.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
1 引文 斯高帕斯（Scopus） -
Corrigendum to “N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression”[Eur. J. Med. Chem. 2020 Jan 1;185:111725] (European Journal of Medicinal Chemistry (2020) 185, (S0223523419308773), (10.1016/j.ejmech.2019.111725))
Mehndiratta, S., Lin, M. H., Wu, Y. W., Chen, C. H., Wu, T. Y., Chuang, K. H., Chao, M. W., Chen, Y. Y., Pan, S. L., Chen, M. C. & Liou, J. P., 8月 1 2020, 於: European Journal of Medicinal Chemistry. 199, 112406.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取1 引文 斯高帕斯（Scopus）